Identification of a pyridine derivative inducing senescence in ovarian cancer cell lines via P21 activation
© 2017 John Wiley & Sons Australia, Ltd..
Cellular senescence is a state of irreversible cell growth arrest. Increasing evidence suggests that cellular senescence contribute to tumour suppression in vivo. However, only a few anti-cancer drugs have been discovered to induce cellular senescence. Searching for new compounds which can inhibit cancer cell growth by inducing senescence is becoming one of the most attractive research fields. To test the effects of candidate compounds on cancer cell growth, cell proliferation assays, senescence-associated β-galactosidase (SA-β-gal) staining, and flow cytometry assay were performed. Immunofluorescence, western blot, and qRT-PCR experiments were used to further study the molecular mechanisms of the candidate compounds. We demonstrated that a pyridine derivative, 4-(4-fluorophenyl)-2-phenyl-5, 6, 7, 8-tetrahydroquinoline (FPTHQ), from a pool of 46 compounds can induce senescence of ovarian cancer cells in a dose-dependent manner. FPTHQ caused growth inhibition by inducing G0/G1 cell cycle arrest in A2780 cells. Increased activities of SA-β-gal were observed in FPTHQ-treated A2780, OVCAR-3 and SKOV-3 cell lines. In addition, FPTHQ treatment increased the protein levels of MMP3 and the mRNA levels of IL-6 and IL-8 in A2780 cells, indicating the appearance of senescence-associated secretary phenotype (SASP) in the cells. Furthermore, we found that p21 was up-regulated and DNA damage was accumulated in FPTHQ-treated ovarian cancer cells. So far, our data suggest that FPTHQ can induce senescence in multiple ovarian cancer cell lines through activation of p21 signalling pathway by causing excessive DNA damage.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:45 |
|---|---|
| Enthalten in: |
Clinical and experimental pharmacology & physiology - 45(2018), 5 vom: 15. Mai, Seite 452-460 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shang, Dongsheng [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cellular senescence |
|---|
| Anmerkungen: |
Date Completed 16.08.2019 Date Revised 16.08.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/1440-1681.12891 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM278097863 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM278097863 | ||
| 003 | DE-627 | ||
| 005 | 20231225015759.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/1440-1681.12891 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0927.xml |
| 035 | |a (DE-627)NLM278097863 | ||
| 035 | |a (NLM)29143360 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shang, Dongsheng |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Identification of a pyridine derivative inducing senescence in ovarian cancer cell lines via P21 activation |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.08.2019 | ||
| 500 | |a Date Revised 16.08.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2017 John Wiley & Sons Australia, Ltd. | ||
| 520 | |a Cellular senescence is a state of irreversible cell growth arrest. Increasing evidence suggests that cellular senescence contribute to tumour suppression in vivo. However, only a few anti-cancer drugs have been discovered to induce cellular senescence. Searching for new compounds which can inhibit cancer cell growth by inducing senescence is becoming one of the most attractive research fields. To test the effects of candidate compounds on cancer cell growth, cell proliferation assays, senescence-associated β-galactosidase (SA-β-gal) staining, and flow cytometry assay were performed. Immunofluorescence, western blot, and qRT-PCR experiments were used to further study the molecular mechanisms of the candidate compounds. We demonstrated that a pyridine derivative, 4-(4-fluorophenyl)-2-phenyl-5, 6, 7, 8-tetrahydroquinoline (FPTHQ), from a pool of 46 compounds can induce senescence of ovarian cancer cells in a dose-dependent manner. FPTHQ caused growth inhibition by inducing G0/G1 cell cycle arrest in A2780 cells. Increased activities of SA-β-gal were observed in FPTHQ-treated A2780, OVCAR-3 and SKOV-3 cell lines. In addition, FPTHQ treatment increased the protein levels of MMP3 and the mRNA levels of IL-6 and IL-8 in A2780 cells, indicating the appearance of senescence-associated secretary phenotype (SASP) in the cells. Furthermore, we found that p21 was up-regulated and DNA damage was accumulated in FPTHQ-treated ovarian cancer cells. So far, our data suggest that FPTHQ can induce senescence in multiple ovarian cancer cell lines through activation of p21 signalling pathway by causing excessive DNA damage | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a DNA damage | |
| 650 | 4 | |a P21 activation | |
| 650 | 4 | |a cellular senescence | |
| 650 | 4 | |a ovarian cancer | |
| 650 | 4 | |a pyridine derivative | |
| 650 | 7 | |a Cyclin-Dependent Kinase Inhibitor p21 |2 NLM | |
| 650 | 7 | |a Pyridines |2 NLM | |
| 650 | 7 | |a pyridine |2 NLM | |
| 650 | 7 | |a NH9L3PP67S |2 NLM | |
| 700 | 1 | |a Wu, Yanfang |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, Ya |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Ziwen |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Yanting |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Feifei |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Hanqing |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Chunyin |e verfasserin |4 aut | |
| 700 | 1 | |a Tu, Zhigang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and experimental pharmacology & physiology |d 1974 |g 45(2018), 5 vom: 15. Mai, Seite 452-460 |w (DE-627)NLM000108138 |x 1440-1681 |7 nnns |
| 773 | 1 | 8 | |g volume:45 |g year:2018 |g number:5 |g day:15 |g month:05 |g pages:452-460 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/1440-1681.12891 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 45 |j 2018 |e 5 |b 15 |c 05 |h 452-460 | ||